Hoffmann-la Roche

This study tested whether adding tiragolumab to atezolizumab (both immunotherapy drugs) helps prevent lung cancer from coming back in people who had surgery and chemotherapy. It included 56 adults with a specific type of lung cancer (PD-L1 positive, stages IIB–IIIB). The main goa…

This study looked at how safe and tolerable the drug risdiplam is for people with spinal muscular atrophy (SMA), a genetic disease that weakens muscles. It included 174 adults, children, and infants who had already tried other SMA treatments. Researchers monitored side effects an…

This study tested a monthly injection called Mircera in 75 adults with chronic kidney disease and anemia who were not yet on dialysis. The goal was to see if the drug could safely raise and maintain healthy hemoglobin levels. Participants received shots under the skin for 3 to 12…

This study looked at how well and how safely the drug ocrelizumab works over a longer period for people with multiple sclerosis (MS). Over 1,000 participants who had already been in earlier Roche studies took part. The goal was to see if the drug could keep disability from gettin…

This study tested a new way to give two powerful breast cancer drugs (pertuzumab and trastuzumab) as a single shot under the skin instead of through an IV drip. It included 200 Chinese patients with HER2-positive early breast cancer. The goal was to see if the shot works as well …

This study looked at how well the drug MIRCERA controls anemia in 144 adults with moderate chronic kidney disease (stages 3-4) who are not yet on dialysis. Researchers tracked hemoglobin levels and safety over 12 months in real-world clinics. The goal was to see if patients reach…

This early-phase study tested a new drug called forimtamig in 225 people with multiple myeloma that had returned or not responded to treatment. Participants had already tried standard therapies and had few options left. The main goals were to check the drug's safety and find the …

This study observed 178 Chinese patients with HER2-positive advanced breast cancer who received the drug T-DM1 after earlier treatments failed. Researchers tracked side effects and how long the drug kept the cancer from growing in real-world settings. The goal was to confirm the …

This study tested several new drug combinations in 281 adults with chronic hepatitis B who already take standard antiviral medication. The goal was to see if these combinations could clear the hepatitis B surface antigen (HBsAg) from the blood, which is a sign of better disease c…

This study tested a new combination of two drugs, obinutuzumab and venetoclax, against the standard combination of obinutuzumab and chlorambucil in 445 people with chronic lymphocytic leukemia (CLL) who also had other health problems. The goal was to see which combination worked …

This study tested a new combination of drugs (venetoclax and obinutuzumab) against standard chemotherapy (FCR or BR) in 166 fit patients with untreated chronic lymphocytic leukemia (CLL) who do not have certain genetic mutations. The goal was to see if the new combo could better …

This study tested whether adding pertuzumab to the usual chemotherapy plus trastuzumab could better prevent breast cancer from returning in people with operable HER2-positive breast cancer. Over 4,800 participants were randomly assigned to receive either the extra drug or a place…

This study tested a new medicine called RO7200220 (vamikibart) given as an eye injection for people with diabetic macular edema, a condition where diabetes causes swelling in the center of the retina and blurs vision. About 394 participants received either the new drug or an acti…

This study tested whether adding the drug polatuzumab vedotin to a standard chemotherapy regimen (R-GEMOX) helps people with relapsed or refractory diffuse large B-cell lymphoma, a type of blood cancer that has returned or not responded to prior treatment. About 270 adults partic…